Agent GuidancecriticalDEA Office of Diversion Control / FDA Center for Food Safety and Applied NutritionDecember 5, 2024
The Drug Enforcement Administration and the Food and Drug Administration issued the first joint federal guidance document specifically addressing hemp-CBD product regulatory boundaries in December 2024.
The joint guidance emerged from Congressional pressure following the 2023 he…
Scheduling ActionhighDEA Office of Diversion ControlNovember 14, 2024
The Drug Enforcement Administration initiated a formal scheduling review for psilocybin and psilocin in November 2024, responding to three FDA Breakthrough Therapy Designations granted to clinical programs developing psilocybin-assisted psychotherapy for treatment-resistant depre…
Asset ForfeituremediumDEA Asset Forfeiture SectionOctober 11, 2024
The Drug Enforcement Administration updated its internal administrative forfeiture threshold for cannabis-linked currency seizures in October 2024, raising the threshold from $30,000 to $50,000 at which DEA's Asset Forfeiture Section must seek judicial forfeiture proceedings rath…
Agent GuidancelowDEA Diversion Control DivisionSeptember 5, 2024
The Drug Enforcement Administration's Diversion Control Division issued updated field guidance in September 2024 on the use of the Controlled Substances Ordering System (CSOS) for Schedule I substance transfers in the context of expanded research authorization under the Consolida…
DEA-DOJ CoordinationhighDEA Office of Diversion Control / DOJ Criminal DivisionAugust 22, 2024
The Department of Justice and the Drug Enforcement Administration issued a joint memorandum in August 2024 addressing banking compliance expectations for financial institutions that choose to provide services to state-licensed cannabis businesses.
The memorandum does not create …
Registration ActionmediumDEA Office of Diversion ControlJuly 18, 2024
The Drug Enforcement Administration issued guidance on July 18, 2024 addressing the intersection of tribal cannabis programs and DEA registration requirements under 21 U.S.C. § 823.
The guidance responds to questions from tribal nations operating cannabis programs pursuant to Un…
CSA AssessmentcriticalDEA Office of Diversion ControlJune 28, 2024
The Drug Enforcement Administration formally initiated controlled substance scheduling assessments for five hemp-derived cannabinoids in June 2024, triggering the eight-factor analysis under 21 U.S.C. § 811 that precedes any formal scheduling rulemaking.
The cannabinoids under a…
Rule ProposalcriticalDEA Office of Diversion ControlMay 21, 2024
On May 21, 2024, the Drug Enforcement Administration published a Notice of Proposed Rulemaking (NPRM) in the Federal Register proposing to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act.
This follows the August 2023 recommendation from the De…
Enforcement RaidhighDEA Los Angeles Field DivisionApril 9, 2024
The DEA Los Angeles Field Division, coordinating with the California Department of Cannabis Control (DCC), the Los Angeles County Sheriff's Department, and the IRS Criminal Investigation division, executed 23 simultaneous search warrants targeting California cannabis operators in…
Cease & DesisthighDEA Diversion Control DivisionMarch 14, 2024
The Drug Enforcement Administration, coordinating with state attorneys general and state pharmacy boards in 14 states, issued cease-and-desist letters to 87 retail establishments selling delta-8 THC products in March 2024.
The action cites DEA's 2021 Interim Final Rule (IFR) cla…
